News | 06 September 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The company has been sold to Shinshin Pharmaceuticals
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
PPH is associated with almost 20 per cent of maternal mortality in India
.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
The facility has the capacity to produce one crore doses per day
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company has to approach the DCGI for approval to commence the trials
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Subscribe To Our Newsletter & Stay Updated
